This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

After being absorbed by the digestive tract, it is converted into active metabolites in the body. Its active metabolites exert analgesic, anti-inflammatory and antipyretic effects by inhibiting the synthesis of prostaglandins.

Cefadroxil is a first-generation oral cephalosporin with good antibacterial effect on most strains of penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pneumoniae, group A hemolytic Streptococcus, etc. It also has certain antibacterial activity against Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae, and gonococci. Methicillin-resistant Staphylococci, Enterococci, indole-positive Proteus, Enterobacter, Serratia and other Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis are resistant to this product. Pharmacology Cefadroxil is low toxic.